Close

Zogenix (ZGNX) Announces Top-Line Results From Relday Phase 1b Trial

September 30, 2015 8:06 AM EDT Send to a Friend
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login